In a recent announcement, ANI Pharmaceuticals has received FDA approval to launch a delayed-release form of naproxen, a key ingredient in the popular pain reliever Aleve. New Approval for Delayed-Release Naproxen ANI Pharmaceuticals has recently obtained approval from the Food and Drug Administration to introduce a delayed-release form of naproxen, which is widely used for treating moderate pain and inflammation, as well as arthritis. Commitment to Innovation Nikhil Lalwani, CEO of ANI, stated, "ANI remains committed to driving growth through superior new product launch execution, in keeping with our purpose of 'Serving Patients, Improving Lives.'" Generic Version of EC-Naprosyn The delayed-release naproxen by ANI is a generic alternative to the EC-Naprosyn brand manufactured by UK-based Pharmanovia. This new product allows patients to take fewer doses as the drug takes longer to enter the bloodstream. Increasing Preference for Delayed-Release Medications Tim Gallagher, director of retail and specialty pharmacy for Allina Health, noted that patients prefer medicines that require fewer tablets or capsules. The ANI delayed-release naproxen comes in 375 milligrams and 500 milligrams, requiring a prescription. Common Medication with Market Competition Despite the popularity of naproxen, other companies also offer delayed-release versions of the drug. Patients can still purchase over-the-counter brands of naproxen, including Aleve, with a recommended dosage every 12 hours. ANI's Business Expansion ANI Pharmaceuticals recently made headlines with a $381 million deal to acquire Alimera Sciences, a Georgia-based company known for its drugs targeting specific eye conditions. This move is expected to strengthen ANI's rare-disease business. Continued Growth and Projections ANI Pharmaceuticals, with three manufacturing facilities in the U.S., has projected revenue of $520 million to $542 million for this year, indicating a sales increase of 7% to 11%.